Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2003

View Archived Issues

PH-027, a novel antimicrobial agent, has potent activity against anaerobic bacteria

NO blocks platelet-leukocyte aggregate formation in acute respiratory distress syndrome

Cathepsin B as a therapeutic target in cancer and arthritis

Duloxetine for painful diabetic neuropathy

Rapid absorption and onset of action for insulin glulisine in dogs and humans

Novel cathepsin K inhibitors in GSK development pipeline

ACAT inhibitors prepared and tested at Takeda

Yamanouchi scientists describe new PARP inhibitors and their use

Shionogi patent describes new antidiabetic agents

Novel group II mGluR antagonists under study at Taisho

Beneficial effects described for inhaled insulin in type 2 diabetes

Potential role for ruboxistaurin in diabetic microvascular complications

Acetyl-CoA carboxylase inhibitors, their preparation and use claimed by Ajinomoto

Neuroprotective effects of AT-1015 in rats with diabetic neuropathy

Mechanism of protective effects of pyridoxamine against diabetic nephropathy

Second approvable letter issued for duloxetine

TLK-286 awarded fast track status for advanced ovarian cancer

Avandia label expanded in Europe

New PPARalpha activator improves insulin sensitivity and lipid profiles in primates

HIM2 effects on glucose production and disposal in nondiabetic subjects

Rifaximin efficacy confirmed in phase III travelers' diarrhea trial

Satraplatin phase III trial cleared to begin

Paxil CR approved for premenstrual dysphoric disorder

BMS returns quinolone antibiotic to Toyama

Bifeprunox to enter phase III development for schizophrenia

FluMist available for 2003-2004 influenza season

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...